Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:20 12/03/2026 GMT			5-day change	1st Jan Change
12.40 ^HKD	-2.52%		+12.52%	-4.69%

03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT
03-11	Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061	RE

Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on March 3, 2025.

Published on 09/15/2025 at 01:05 pm BST - Modified on 09/15/2025 at 09:30 am BST

S&P Capital IQ

ABBISKO CAYMAN LIMITED

-2.52%

From March 3, 2025 to June 30, 2025, the company has repurchased 300,000 shares, representing 0.05% for HKD 3.03 million. With this, the company has completed the repurchase of 300,000 shares, representing 0.05% for HKD 3.03 million under the buyback announced on March 3, 2025.

Latest news about Abbisko Cayman Limited

03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT
03-11	Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061	RE
03-04	Abbisko Doses First Patient in Tumor Drug Trial	MT
03-03	Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share	RE
03-03	Abbisko Profit Nearly Doubles in 2025	MT
03-02	Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-11	Abbisko Unit Doses First U.S. Patient in Phase 1 Study of Liver Cancer Drug	MT
02-10	Abbisko Therapeutics Co., Ltd. Announces First Patient in the Expansion Part of A Global Phase I Study	CI
02-10	Abbisko Drug Secures Fast Track Designation in U.S.	MT
02-10	Abbisko Cayman says FDA grants fast track designation to Abbisko's irpagratinib	RE
01-13	Abbisko Cayman's new drug application for pimicotinib formally accepted by U.S. FDA	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT
01-13	Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	CI
12-24	Abbisko Unit Gets China Investigational New Drug Clearance for Tumor Drug	MT
12-24	Abbisko Cayman says NMPA clears IND application for unit's Abbisko's Absk141	RE

Chart Abbisko Cayman Limited

Duration

Period

2256: Dynamic Chart

Company Profile

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâ€™s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Employees

226

Sector

Biotechnology & Medical Research

More about the company